logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Pharmaceutical stocks fell sharply, with innovative drugs leading the decline.

date
04/08/2025
In the early trading session, pharmaceutical stocks continued to decline, with Kexing Pharmaceutical and Biogu falling over 11%, and Aoxiang Pharmaceutical, Shenglian Biological, Anke Biological, Zhongsheng Pharmaceutical, Haichuang Pharmaceutical and other stocks falling over 6%.
Latest
2 m ago
Dao Mingko Wen: Raising Ralph Lauren Company's target price from 308 US dollars to 340 US dollars.
2 m ago
Domingo Castro: Raises Ralph Lauren company's target price from $308 to $340.
3 m ago
Beijing upgrades to release orange warning for geological disaster meteorological risks.
3 m ago
UBS Group: UBS is expected to confirm in the third quarter of 2025 a credit income from non-core and legacy businesses. This income is derived from the release of contingent liabilities established in the purchase price allocation process for the acquisition of Swiss Credit.
3 m ago
UBS Group: In the third quarter of 2025, UBS expects to recognize credit revenue from non-core and legacy businesses, which is derived from the release of contingent liabilities established in the purchase price allocation process for the acquisition of Credit Suisse.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.